MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 7 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

venueno affunlabeled
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni +11 more
2022· article· en· Current Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
6
citations
affunlabeled
Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) from BYLieve.
Stephen Chia, Manuel Ruíz‐Borrego, Pamela Drullinsky, Dejan Juric, Thomas Bachelot, Hope S. Rugo +7 more
2021· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
6
citations
affunlabeled
Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
Dejan Juric, Nicholas Turner, Aleix Prat, Stephen Chia, Eva Ciruelos, Manuel Ruíz‐Borrego +9 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+sts+research_integrity+insufficient_payloadconsensus · none
6
citations
affunlabeled
Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for <i>HER2</i>-mutant, hormone receptor-positive, metastatic breast cancer
Komal Jhaveri, Cristina Saura, Ángel Guerrero‐Zotano, Iben Spanggaard, François‐Clément Bidard, Jonathan W. Goldman +22 more
2021· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
5
citations
affno abstractunlabeled
VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)
Peter A. Fasching, Dennis J. Slamon, Zbigniew Nowecki, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley +14 more
2023· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
5
citations
affunlabeled
Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or &amp;gt;6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) from BYLieve
Stephen Chia, Eva Ciruelos, Hope S. Rugo, Florence Lerebours, Manuel Ruíz‐Borrego, Pamela Drullinsky +7 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
5
citations
affunlabeled
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
Dejan Juric, Kevin Kalinsky, Seock‐Ah Im, Eva Ciruelos, Giampaolo Bianchini, Carlos H. Barrios +9 more
2024· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
5
citations
← previousnext →

How this was built: Screen · Findings · About